We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Guardant Health, Inc. is one ...

Tuesday, the FDA's staff reviewers raised concerns regarding Guardant Health Inc's (NASDAQ:GH) experimental blood test for colorectal cancer, suggesting it might not detect some tumor types that could ...

On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.’s (NASDAQ:GH) Shield blood test for colorectal ...

Guardant Health (NASDAQ:GH) said its recently approved blood test Shield for the detection of colorectal cancer has been commercially launched in the U.S. The diagnostics maker said Medicare will ...

Guardant Health, Inc. (NASDAQ:GH) and research collaborators have unveiled results from the largest study to date on circulating tumor DNA (ctDNA) testing in stage III colon cancer, presented at the ...

Tesamorelin is a synthetic 44–amino acid analog of growth hormone–releasing hormone (GHRH) that has attracted attention outside the experimental domain for its potential as a research tool. This ...

Guardant Health (NASDAQ:GH) shares turned lower on Tuesday after FDA staffers commented on its Shield blood test for colorectal cancer screening (CRC) ahead of an advisory committee meeting later this ...

A new study by researchers at the University of São Paulo (USP) in Brazil has provided a better understanding of the role of one hormone – growth hormone (GH) – in anxiety, for the first time ...